EBC-46

Blood Markers, Doctor Reactions, and the Blushwood Reports That Demand Scientific Attention

When a doctor looks up blushwood extract after seeing unexplained improvements in a patient's blood work, something remarkable is happening — and the scientific community should be paying attention.

EBC-46

The Diterpene Ester Family: Where EBC-46 Fits in Plant-Derived Chemistry

EBC-46 belongs to the diterpene ester class — a family of plant compounds with extraordinary biological potency. Understanding this chemical context reveals why the Blushwood berry has captivated researchers.

EBC-46

Patient Selection in EBC-46 Trials: Who Qualifies and Why Tumour Accessibility Matters

Not every cancer patient qualifies for EBC-46 clinical trials. Tumour accessibility, prior treatment history, and lesion characteristics all determine eligibility — here is what the inclusion criteria reveal.

EBC-46

Vascular Disruption Without Systemic Toxicity: How EBC-46 Starves Tumours From Within

EBC-46 destroys the blood vessels feeding a tumour within hours of injection — cutting off oxygen and nutrients while leaving surrounding healthy vasculature intact. Here is the biology behind this precision.

EBC-46

Compassionate Use Pathways for Tigilanol Tiglate: How Patients Access Unapproved Cancer Drugs

Compassionate use and expanded access programmes could allow cancer patients to receive tigilanol tiglate before formal Phase III approval — here is how the regulatory framework works.

EBC-46

Hylandia dockrillii vs Fontainea picrosperma: The Blushwood Misidentification That Has Misled the Internet for a Decade

Two plants share the name Blushwood, but only one contains EBC-46. A decade of media misidentification has wrongly attributed tigilanol tiglate to Hylandia dockrillii — here is the full story.

EBC-46

Topical Blushwood Berry Extract: What Users Report and What the Science Says

Verified buyers report striking results with blushwood berry extract — from inflammation and energy to skin changes and outcomes that surprised their doctors. Science should be paying attention.

EBC-46

Fontainea picrosperma: The Rainforest Tree That Produces EBC-46

Fontainea picrosperma grows only in north Queensland's Wet Tropics and produces a pharmacologically extraordinary compound. The full extent of what it can do remains one of botany's most compelling open questions.

EBC-46

EBC-46 in Human Clinical Trials: Phase I Safety Data and What It Tells Us

Phase I human trials of tigilanol tiglate are evaluating safety in solid tumours. Early data suggests the tolerability profile mirrors what was observed in veterinary studies.

EBC-46

PKC-Delta Activation: The Molecular Switch Behind EBC-46's Anti-Tumour Effect

EBC-46 works by mimicking diacylglycerol to activate PKC-delta, triggering a cascade of vascular disruption and immune recruitment that destroys tumours from within.

EBC-46

Stelfonta's FDA Approval: What the Regulatory Pathway Tells Us About EBC-46's Future

Stelfonta became the first tigilanol tiglate product approved by the FDA. Understanding its regulatory journey maps the path EBC-46 must follow for human approval.

EBC-46

Tigilanol Tiglate Pharmacokinetics: What Happens After an EBC-46 Injection?

Intratumoral EBC-46 is designed to stay local — but how much reaches systemic circulation, and what does the body do with it? A detailed look at tigilanol tiglate pharmacokinetics.